These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 28113109

  • 1. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K, Jain T, Kosiorek H, Tibes R, Camoriano J, Palmer J, Mesa R.
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [Abstract] [Full Text] [Related]

  • 2. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
    Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R.
    Haematologica; 2012 Oct; 97(10):1570-3. PubMed ID: 22419578
    [Abstract] [Full Text] [Related]

  • 3. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
    Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S.
    Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
    [Abstract] [Full Text] [Related]

  • 4. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL, Subortseva IN, Gilyazitdinova EA, Koloshejnova TI, Pustovaya EI, Egorova EK, Kovrigina AM, Sudarikov AB, Abdullaev AO, Lomaia EG, Siordiya NT, Zaritskey AY, Savchenko VG.
    Ter Arkh; 2018 Aug 17; 90(7):23-29. PubMed ID: 30701919
    [Abstract] [Full Text] [Related]

  • 5. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL, Tiu RV.
    J Interferon Cytokine Res; 2013 Apr 17; 33(4):145-53. PubMed ID: 23570380
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.
    Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, De Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ.
    Br J Haematol; 2013 Sep 17; 162(6):783-91. PubMed ID: 23848933
    [Abstract] [Full Text] [Related]

  • 7. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
    Kucine N, Bergmann S, Krichevsky S, Jones D, Rytting M, Jain J, Bennett CM, Resar LMS, Mascarenhas J, Verstovsek S, Hoffman R.
    Pediatr Blood Cancer; 2021 Mar 17; 68(3):e28888. PubMed ID: 33381905
    [Abstract] [Full Text] [Related]

  • 8. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
    O'Neill C, Siddiqi I, Brynes RK, Vergara-Lluri M, Moschiano E, O'Connell C.
    Ann Hematol; 2016 Apr 17; 95(5):733-8. PubMed ID: 26961933
    [Abstract] [Full Text] [Related]

  • 9. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
    Mazza GL, Mead-Harvey C, Mascarenhas J, Yacoub A, Kosiorek HE, Hoffman R, Dueck AC, Mesa RA, Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams.
    Lancet Haematol; 2022 Jan 17; 9(1):e38-e48. PubMed ID: 34971581
    [Abstract] [Full Text] [Related]

  • 10. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H, Leung GMK, Yim R, Lee P, Pang HH, Ip HW, Leung RYY, Li J, Panagiotou G, Ma ESK, Kwong YL.
    Hematology; 2020 Dec 17; 25(1):247-257. PubMed ID: 32567517
    [Abstract] [Full Text] [Related]

  • 11. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
    Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R.
    Leukemia; 2019 Dec 17; 33(12):2974-2978. PubMed ID: 31363161
    [No Abstract] [Full Text] [Related]

  • 12. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.
    Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ.
    Haematologica; 2018 Mar 17; 103(3):438-446. PubMed ID: 29217781
    [Abstract] [Full Text] [Related]

  • 13. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
    Talpaz M, Kurzrock R, Kantarjian H, O'Brien S, Gutterman JU.
    Am J Med; 1989 May 17; 86(5):554-8. PubMed ID: 2712063
    [Abstract] [Full Text] [Related]

  • 14. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
    Samuelsson J, Mutschler M, Birgegård G, Gram-Hansen P, Björkholm M, Pahl HL.
    Haematologica; 2006 Sep 17; 91(9):1281-2. PubMed ID: 16956836
    [Abstract] [Full Text] [Related]

  • 15. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 16. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
    Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R.
    Blood; 2019 Oct 31; 134(18):1498-1509. PubMed ID: 31515250
    [Abstract] [Full Text] [Related]

  • 17. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
    Hasselbalch HC.
    Expert Rev Hematol; 2011 Dec 31; 4(6):637-55. PubMed ID: 22077528
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
    Hasselbalch HC, Holmström MO.
    Semin Immunopathol; 2019 Jan 31; 41(1):5-19. PubMed ID: 30203226
    [Abstract] [Full Text] [Related]

  • 20. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May 31; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.